@Article{Woźniak2014,
journal="Menopause Review/Przegląd Menopauzalny",
issn="1643-8876",
volume="13",
number="1",
year="2014",
title="The effect of ulipristal acetate treatment on symptomatic uterine fibroids within 12-months follow-up",
abstract=" Aim of the study:  The purpose of the study was to monitor the effect of ulipristal acetate treatment on symptomatic uterine fibroids within 12-months follow-up.   Material and methods : Fifty six patients with symptomatic uterine fibroids qualified for surgical treatment were included in the prospective observational study. All patients received preoperative oral UPA treatment for 3 months (1 × 5 mg). Patients that refused surgical treatment after UPA therapy were followed-up for the next 9 months. The volume of the intramural fibroid was estimated by TV-US using and integrated VOCAL 3D imaging program at baseline, after 3 months of UPA treatment and further at 3-months intervals.   Results:  Before UPA mean dominant fibroid volume was estimated to be 216.0 cm3 (38.4-768.2 cm 3 ) and decreased to 117.6 cm 3  (12.6-668.0 cm 3 ) after 3 months of UPA therapy. Mean percentage volume reduction was 45.6%. Mean hemoglobin level increased from an initial 10.1 g/dL (6.8-12.9 g/dL) to 12.6 g/dL (10.1-14.8) after 3 months of UPA therapy. At 12 months after initiating UPA treatment mean dominant fibroid volume decreased by 43.9%. In one third of followed-up patients the effect of 3 month UPA therapy persisted for the next 9 months.   Conclusions : Three month UPA therapy decreases fibroid volume and improves hemoglobin level before planned surgical treatment. In one third of followed-up patients the effect of 3 month UPA therapy persisted for the next 9 months.",
author="Woźniak, Sławomir
and Szkodziak, Piotr
and Czuczwar, Piotr
and Woźniakowska, Ewa
and Paszkowski, Maciej
and Milart, Paweł
and Paszkowski, Tomasz",
pages="18--21",
doi="10.5114/pm.2014.41091",
url="http://dx.doi.org/10.5114/pm.2014.41091"
}